- Home
- ARQT vs VNET Comparison
ARQT vs VNET Comparison
Compare ARQT & VNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- VNET
- Stock Information
- Founded
- ARQT 2016
- VNET 1999
- Country
- ARQT United States
- VNET China
- Employees
- ARQT N/A
- VNET N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- VNET Computer Software: Programming Data Processing
- Sector
- ARQT Health Care
- VNET Technology
- Exchange
- ARQT Nasdaq
- VNET Nasdaq
- Market Cap
- ARQT 1.7B
- VNET 1.7B
- IPO Year
- ARQT 2020
- VNET 2011
- Fundamental
- Price
- ARQT $13.89
- VNET $6.61
- Analyst Decision
- ARQT Strong Buy
- VNET Strong Buy
- Analyst Count
- ARQT 6
- VNET 3
- Target Price
- ARQT $18.80
- VNET $10.73
- AVG Volume (30 Days)
- ARQT 1.9M
- VNET 4.8M
- Earning Date
- ARQT 08-13-2025
- VNET 05-28-2025
- Dividend Yield
- ARQT N/A
- VNET N/A
- EPS Growth
- ARQT N/A
- VNET N/A
- EPS
- ARQT N/A
- VNET N/A
- Revenue
- ARQT $212,819,000.00
- VNET $1,186,131,469.00
- Revenue This Year
- ARQT $61.15
- VNET $15.44
- Revenue Next Year
- ARQT $37.98
- VNET $19.86
- P/E Ratio
- ARQT N/A
- VNET $109.26
- Revenue Growth
- ARQT 100.03
- VNET 14.68
- 52 Week Low
- ARQT $7.86
- VNET $1.71
- 52 Week High
- ARQT $17.75
- VNET $16.13
- Technical
- Relative Strength Index (RSI)
- ARQT 51.91
- VNET 58.59
- Support Level
- ARQT $13.47
- VNET $5.80
- Resistance Level
- ARQT $14.69
- VNET $7.29
- Average True Range (ATR)
- ARQT 0.63
- VNET 0.33
- MACD
- ARQT 0.05
- VNET 0.16
- Stochastic Oscillator
- ARQT 68.53
- VNET 65.66
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About VNET VNET Group Inc.
VNET started as AsiaCloud in 1999 and moved to the data center business with its first self-developed data center opening in 2010. The firm listed (as 21Vianet) on the Nasdaq in April 2011, subsequently changing its name to VNET Group in 2021. It originally focused on providing data center services such as colocation and cloud services to retail clients in China, but added hyperscale customers in 2019 and now counts large Chinese hyperscalers such as Alibaba Cloud, Tencent Cloud, and Huawei Cloud as customers. At the end of June 2024, it had 48,516 self-built retail cabinets with the majority in Beijing, Shanghai, and the Greater Bay area. It also had 358 MW of wholesale capacity in service with a further 297 MW under construction and a further 489 MW held for future development.